UBS Group
LBRX

UBS Group’s LB Pharmaceuticals LBRX Stock Holding History

UBS Group’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.4M Buy
137,932
+87,219
+172% +$2.01M ﹤0.01% 4463
2025
Q4 		$1.13M Buy
50,713
+49,658
+4,707% +$867K ﹤0.01% 5462
2025
Q3 		$16.7K Buy
+1,055
New +$16.7K ﹤0.01% 8276

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group's LBRX Position: Q1 2026 in Review

UBS Group increased its LB Pharmaceuticals (LBRX) stake by 172% in Q1 2026, buying an estimated $2.01M and bringing the position to 137,932 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #4463.

UBS Group first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • UBS Group held 137,932 shares of LB Pharmaceuticals worth $3.4M as of Q1 2026.
  • UBS Group bought 87,219 LB Pharmaceuticals shares in Q1 2026, an estimated $2.01M.
  • LB Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4463 holding.
  • UBS Group first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.